Updated:
VC23
VC23 Ventures is biotools-focused capital investing in life science and beyond. The firm backs companies shaping the next 20 years of biology and states it...
Overview
VC23 Ventures is biotools-focused capital investing in life science and beyond. The firm backs companies shaping the next 20 years of biology and states it does not just invest in biotech but helps make it smarter. It uses proprietary analytics and AI-enhanced diligence to evaluate scientific, financial, and market data. VC23 invests across all sectors but focuses on BioTools because they generally scale faster and more efficiently than therapeutics, reach revenue and partnerships earlier, and often require less capital before exit.
General information
Firm type
Private Equity
Location
Region
North America
Country
United States
City
Avon
Corporate office
Avon, CT, United States
Sector focus
Frequently asked questions
Which sectors does VC23 explicitly target?
VC23 concentrates on enterprise software, applied AI and machine learning, fintech infrastructure, and digital health. The firm looks for B2B companies with technical moats. It has not publicly disclosed interest in consumer internet, hardware, or capital-intensive climate-tech verticals.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: